Pfizer Shakes Up R&D Leadership, Streamlining Oncology Ahead Of Seagen Merger

 
• By Jessica Merrill
  
Generate a summary of this article
Listen to this article
Beta

Chief development officer William Pao will depart the company in a sudden transition after being recruited from Roche. Pfizer insiders Chris Boshoff and Mikael Dolsten will fill the roles.

Exit door
William Pao is leaving Pfizer's R&D team • Source: Shutterstock

Pfizer Inc. revealed a sudden leadership transition on 27 July, announcing that chief development officer William Pao will leave the company after taking over clinical development oversight just over a year ago. Pfizer said the change is driven by an emphasis on oncology and the pending acquisition of Seagen Inc. , the big pharma actively recruited Pao from a major player in cancer drug development – Roche Holding AG – and he previously worked in academia as a cancer researcher.

Key Takeaways

  • R&D leader William Pao will leave Pfizer after only joining the company from Roche last year.

Two experienced Pfizer executives are poised to fill in the gap, with oncology chief development officer Chris Boshoff promoted to...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Leadership

ProGen’s Dual Agonist Obesity Contender Gains Momentum With Rani Partnership

 
• By Jung Won Shin

The CEO of South Korean biotech shares how his company was able to reach a partnership with Rani so quickly and why it is confident in its GLP-1/GLP-2 dual agonist for obesity and diabetes, despite recent disappointing clinical results for its sole rival.

Scrip-Leadership (Free-2): Titans Of Pharma: Lilly’s Ricks Tops Big Pharma Pay Chart

 
• By Nabil

The big pharma CEO with the highest-valued compensation in 2024 was David Ricks of Eli Lilly, while Pfizer and J&J executives slipped into third and fourth place behind AbbVie's now retired chief Richard Gonzalez. European firms brought up the rear.

As More DLL3 Bispecifics Advance, Doctors Are Adjusting To CRS, ICANS

 
• By Mandy Jackson

Amgen’s Imdelltra for small-cell lung cancer is one of two bispecific T-cell engagers approved for solid tumors, but data at the WCLC meeting show other DLL3-targeting BiTEs may be on the way.

Novo Nordisk’s Semaglutide Shows Promise In Hidradenitis Suppurativa

 
• By Andrew McConaghie

An academic study of GLP-1 agonist showed promise in patients with the painful skin condition but with no signs that the Danish drugmaker will pursue the indication, smaller players in the space may be interested.

More from Scrip

EHA: Lilly’s Jaypirca Posts First Phase III Triplet Win In CLL While BTK Degraders Advance - Clone

Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.

Top 10 Drugs Q1 2026: New Sheriff In Town As Mounjaro Unseats Keytruda

Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains